New lipidic peptide IK14004 shows promise in treating cancer and reducing autoimmune complications

A lipidic peptide, named IK14004.

FDA grants priority review to AstraZeneca’s Imfinzi sBLA for MIBC

AstraZeneca’s sBLA submission is supported by outcomes from a multi-centre Phase III trial. Credit: © AstraZeneca 2024. The US Food and Drug Administration (FDA) has

December 9, 2024

Cell therapy commercialization: Streamline your path to cell therapy commercialization

Moving your cell therapy clinical trial beyond Phase I is an exciting time, marking a significant milestone. There are many therapeutic developers working to address

August 28, 2024

Graduate students accuse University of California of wage theft, just months after strike was settled

University of California graduate students were thrilled last December when they won what they thought were big pay increases after an unprecedented strike. Most of

September 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.